---
title: 'Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and
  Hyperthermic Intrathoracic Chemotherapy: Impact of Additive Chemotherapy'
date: '2024-04-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38672669/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240427180604&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Cytoreductive surgery (CRS) combined with hyperthermic intrathoracic
  chemoperfusion (HITOC) is a promising treatment strategy for pleural mesothelioma
  (PM). The aim of this study was to evaluate the impacts of this multimodal approach
  in combination with systemic treatment on disease-free survival (DFS) and overall
  survival (OS). In this retrospective multicenter study, clinical data from patients
  after CRS and HITOC for PM at four high-volume thoracic surgery departments in Germany
  ...
disable_comments: true
---
Cytoreductive surgery (CRS) combined with hyperthermic intrathoracic chemoperfusion (HITOC) is a promising treatment strategy for pleural mesothelioma (PM). The aim of this study was to evaluate the impacts of this multimodal approach in combination with systemic treatment on disease-free survival (DFS) and overall survival (OS). In this retrospective multicenter study, clinical data from patients after CRS and HITOC for PM at four high-volume thoracic surgery departments in Germany ...